Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer

J. M. Cain, C. Collins, S. Petersdorf, D. C. Figge, H. K. Tamimi, B. E. Greer, R. B. Livingston, J. B. Schlaerth, I. Golditch

Research output: Contribution to journalArticle

8 Scopus citations

Abstract

OBJECTIVES: A phase II trial of high-dose cyclophosphamide, etoposide, and cisplatin was done. STUDY DESIGN: Forty-eight patients with progressive or persistent disease and previous cisplatin-based chemotherapy and no paclitaxel therapy were entered for treatment on the basis of two cycles of cyclophosphamide (4500 mg/m2), etoposide (750 mg/m2), and cisplatin (120 mg/m2). RESULT: Seventy-four cycles were delivered. Six patients died during treatment (12.5%). Of 28 with measurable disease, there was a 25% response rate and 32% had stable disease. Median time to recurrence and survival were significantly different for minimal versus bulky disease (p = 0.0089, p = 0.0008, log-rank) and for platinum-sensitive versus platinum-resistant disease (p = 0.18, p = 0.0012, log-rank). The number of prior regimens was not correlated with time to progression or survival. CONCLUSION: This study shows little advantage for high-dose protocols except for patients with a response to platinating agents and minimal residual disease.

Original languageEnglish (US)
Pages (from-to)1688-1694
Number of pages7
JournalAmerican journal of obstetrics and gynecology
Volume174
Issue number6
DOIs
StatePublished - Jan 1 1996

Keywords

  • Cisplatin
  • cyclophosphamide
  • etoposide
  • ovarian cancer

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Fingerprint Dive into the research topics of 'Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer'. Together they form a unique fingerprint.

  • Cite this

    Cain, J. M., Collins, C., Petersdorf, S., Figge, D. C., Tamimi, H. K., Greer, B. E., Livingston, R. B., Schlaerth, J. B., & Golditch, I. (1996). Phase II study of high-dose cisplatin, etoposide, and cyclophosphamide for refractory ovarian cancer. American journal of obstetrics and gynecology, 174(6), 1688-1694. https://doi.org/10.1016/S0002-9378(96)70198-9